Discontinue Trazodone and Switch to Cognitive Behavioral Therapy for Insomnia (CBT-I) or Consider a Non-Benzodiazepine BZRA
The 2019 VA/DoD clinical practice guidelines explicitly advise AGAINST using trazodone for chronic insomnia disorder, as the evidence supporting its efficacy is low-quality and outweighed by its adverse effect profile 1. At 200 mg, this patient is already at the upper end of the typical dosing range, and continuing to escalate or persist with an ineffective agent is not evidence-based.
Why Trazodone Should Be Discontinued
The guideline review found that trazodone (50-150 mg) showed no differences in sleep efficiency or discontinuation rates compared to placebo in patients with chronic insomnia 1. While it improved subjective sleep quality, it failed to improve objective measures like sleep onset latency, total sleep time, or wake after sleep onset. The studies were short-term (mean 1.7 weeks) with limited follow-up, making the evidence particularly weak 1.
Key problems with continuing trazodone:
- The patient is already on 200 mg (above the studied dose range of 50-150 mg) and still symptomatic
- Evidence of tolerance development has been documented 2
- High discontinuation rates due to adverse effects including sedation, dizziness, and psychomotor impairment 2
- Significant cardiac risks including QT prolongation, arrhythmias, and orthostatic hypotension 3
- Risk of priapism (reported in up to 12% in some studies) 4
Recommended Management Algorithm
Step 1: Assess for Underlying Causes
Before changing therapy, evaluate:
- Depression or other psychiatric comorbidity (trazodone may be appropriate if treating comorbid depression, but as monotherapy for insomnia it lacks support) 5
- Sleep apnea (trazodone can worsen respiratory conditions) 1
- Medications causing insomnia (activating antidepressants, stimulants, corticosteroids)
- Substance use (alcohol, caffeine)
- Medical conditions (pain, nocturia, GERD)
Step 2: First-Line Treatment - CBT-I
Cognitive Behavioral Therapy for Insomnia should be the initial treatment as recommended by the VA/DoD guidelines 1. This has the strongest evidence base without the adverse effects of pharmacotherapy.
Step 3: If Pharmacotherapy Needed
If CBT-I is unavailable or insufficient:
Consider non-benzodiazepine BZRAs (Z-drugs):
- Zolpidem, eszopiclone, or zaleplon
- Use at the lowest effective dose for the shortest duration
- The guidelines found benefits outweigh harms for these agents (unlike trazodone) 1
- Critical caveat: FDA recently warned about serious injuries from complex sleep behaviors (sleepwalking, sleep driving) - counsel all patients on these risks 1
Avoid:
- Benzodiazepines (risk of dependency, falls, cognitive impairment, respiratory depression) 1
- Antihistamines (tolerance develops in 3-4 days, anticholinergic effects particularly dangerous in elderly per Beers Criteria) 1
- Antipsychotics like quetiapine (insufficient evidence, significant harms) 1
Step 4: Taper Trazodone Gradually
Do not abruptly discontinue - trazodone can cause discontinuation syndrome including nausea, dizziness, irritability, and sensory disturbances 3. Reduce by 50 mg every 3-7 days while initiating alternative therapy.
Special Considerations
If the patient has comorbid depression: Trazodone may be continued as adjunctive therapy to an activating antidepressant (SSRI/SNRI), where it can address SSRI-induced insomnia 6. In this context, doses of 50-100 mg are typically sufficient for sleep maintenance 6.
Cardiac screening is essential given the patient's current 200 mg dose. Check for:
- QT interval prolongation on ECG
- History of arrhythmias
- Concurrent QT-prolonging medications
- Electrolyte abnormalities (hypokalemia, hypomagnesemia) 3
Monitor for serious adverse effects:
- Orthostatic hypotension (particularly if on antihypertensives) 3
- Bleeding risk (if on anticoagulants/antiplatelets) 3
- Hyponatremia (especially in elderly, those on diuretics) 3
- Priapism in male patients (requires immediate discontinuation if erection >4 hours) 3
Bottom Line
The evidence does not support continuing or escalating trazodone for primary insomnia at any dose. The patient's persistent symptoms at 200 mg demonstrate treatment failure with an agent that lacks robust efficacy data. Transition to evidence-based therapy (CBT-I first-line, or non-benzodiazepine BZRAs if needed) while tapering trazodone to avoid discontinuation syndrome.